IP Library Granted Patent US 9,198,795
Granted Patent B2
US 9,198,795 · App. 13/784,661 · Granted Dec 1, 2015

Implant delivery device

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,198,795
App. No.
13/784,661
Granted
Dec 1, 2015
Kind
B2
Abstract

Devices and methods are disclosed for the delivery of a compressible implant into a bodily lumen. The delivery device includes an enlarged section that is configured to house the implant during delivery thereof into a patient. In certain embodiments, the implant is kept within the delivery device in a substantially uncompressed configuration prior to the delivery thereof.

Claims (17)

1. A method of implanting a compressible occlusive device in a fallopian tube of a patient, the fallopian tube having an ostium, comprising:

inserting a distal section of an introducer into the fallopian tube until the distal section is adjacent an implant location in the fallopian tube, and such that an intermediate section of the introducer is positioned outside of the fallopian tube adjacent the ostium;

moving the occlusive device from the intermediate section of the introducer into the distal section, wherein the intermediate section has an intermediate section inner diameter, such that the occlusive device, when disposed in the intermediate section, is in a substantially uncompressed configuration, wherein, when the occlusive device is moved from the intermediate section to the distal section, the occlusive device passes through a transition section of the introducer that compresses the occlusive device; and

deploying the occlusive device out a distal opening in the distal section of the introducer and into the fallopian tube at the implant location.

2. The method of claim 1 , wherein the occlusive device has an uncompressed outer diameter.

3. The method of claim 2 , wherein the intermediate section inner diameter is more than 70% of, and less than 100% of, the uncompressed outer diameter.

4. The method of claim 2 , wherein the intermediate section inner diameter is more than 80% of, and less than 100% of, the uncompressed outer diameter.

5. The method of claim 2 , wherein the intermediate section inner diameter is more than 90% of, and less than 100% of, the uncompressed outer diameter.

6. The method of claim 2 , wherein the intermediate section inner diameter is more than 95% of, and less than 100% of, the uncompressed outer diameter.

7. The method of claim 1 , further comprising ablating tissue in the fallopian tube at the implant location prior to deploying the occlusive device.

8. The method of claim 7 , wherein ablating tissue in the fallopian tube comprises delivering RF energy to the tissue in the fallopian tube via the distal section of the introducer.

9. The method of claim 7 , wherein ablating tissue in the fallopian tube at the implant location causes the tissue to constrict around the occlusive device after the occlusive device is deployed into the fallopian tube.

10. The method of claim 1 , wherein moving the occlusive device comprises moving a pusher member in a distal direction relative to the introducer.

11. The method of claim 10 , wherein deploying the occlusive device comprises moving the pusher member in a distal direction relative to the introducer.

12. The method of claim 10 , wherein deploying the occlusive device comprises moving the introducer in a proximal direction relative to the pusher member.

13. The method of claim 1 , wherein inserting the distal section of the introducer into the fallopian tube until the distal section is adjacent the implant location in the fallopian tube comprises inserting the distal section of the introducer into the fallopian tube until the intermediate section of the introducer abuts an ostium of the fallopian tube.

14. The method of claim 1 , wherein the occlusive device is configured to expand after being deployed into the fallopian tube to thereby occlude the fallopian tube.

Assignments (2)
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →